CAMBRIDGE, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Targanta Therapeutics Corporation today announced its participation in the Biotechnology Industry Organization’s CEO & Investor Conference, taking place from February 11th through February 13th at the Waldorf~Astoria Hotel in New York City.
Mark Leuchtenberger, President and Chief Executive Officer of Targanta, will be delivering a corporate presentation at 2:45 pm ET on Monday, February 11th in the Jade Room. A live webcast of this presentation will be accessible via the corporate website at www.targanta.com/investors and available for replay for 30 days.
In addition, Thomas R. Parr, Jr., Ph.D., Targanta’s Chief Scientific Officer, will be participating in the Therapeutic Workshop: Antibiotics: “Super Drugs Against Super Bugs” at 9:30 am ET on Wednesday February 13th in the East Foyer.
About Targanta Therapeutics
Targanta Therapeutics Corporation is a privately held biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company’s pipeline includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic, for which Targanta intends to seek U.S. regulatory approval in early 2008, as well as a number of antibacterial agents in pre-clinical development. The company has operations in Cambridge, MA, Indianapolis, IN, and Montreal, Quebec. For further information about Targanta, visit the company’s website at www.targanta.com.
Safe Harbor Statement
This press release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These are statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “may,” “will,” “expects,” “projects,” “anticipates,” “estimates,” “believes,” “intends,” “plans,” “should,” “seeks,” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that may cause actual future results to differ materially from those projected or contemplated in the forward-looking statements. Forward-looking statements may be significantly impacted by certain risks and uncertainties described in Targanta’s filings with the Securities and Exchange Commission. The risks and uncertainties referred to above include, but are not limited to, risks related to Targanta’s dependence on the success of oritavancin; delays in obtaining or a failure to obtain regulatory approval for Targanta’s product candidates; failure of any approved product to achieve significant commercial acceptance in the medical community or receive reimbursement by third-party payors; unfavorable clinical trial results; failure to maintain and protect Targanta’s intellectual property assets and to avoid infringing the intellectual property rights of others; competition from other pharmaceutical or biotechnology companies; Targanta’s potential inability to initiate and complete pre- clinical studies and clinical trials for its product candidates; the possibility that results of pre-clinical studies are not necessarily predictive of clinical trial results; and those other risks factors that are described more fully in the Company’s filings with the Securities and Exchange Commission. Targanta does not undertake any obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.
CONTACT: George Eldridge (investors), Senior Vice President Finance &
Administration and Chief Financial Officer of Targanta Therapeutics
Corporation, +1-617-577-9020 x212
Web site: http://www.targanta.com/
http://www.targanta.com/investors/
